1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Alpha Cognition entered a settlement agreement dated April 10, 2026 with Galantos Pharma GmbH i.L., a company in liquidation, to extinguish future royalty and milestone payments under the Memogain Asset Purchase Agreement. In exchange for a one-time payment of EUR 5,214,220, Galantos agreed to release the company and its related parties from claims arising from the original agreement. The filing does not state the financial impact on the company's results.
One-time payment of EUR 5,214,220 to Galantos in full satisfaction of remaining contingent obligations, including royalty and milestone-related payments.
Galantos waives and releases the company and its related parties from causes of action arising from the Original Agreement.
Management states the settlement is an approximate 40% discount to the estimated market value of the remaining obligations, based on its own projections and comparable market benchmarks.
Agreement dated April 10, 2026; filed as Exhibit 10.1 to the report signed by CEO Michael McFadden on April 14, 2026.
Albertsons reported a fourth-quarter net loss of $480.8 million, or $0.94 per share, after a $599.8 million after-tax charge tied to a $774 million opioid settlement framework payable over nine years. Excluding the charge and other adjustments, fourth-quarter adjusted net income rose to $251.7 million, or $0.48 per share, from $0.46 a year earlier, and the board raised the quarterly dividend 13% and expanded the buyback authorization.
Q4 fiscal 2025 net loss of $(480.8) million, or $(0.94) per share, versus net income of $171.8 million, or $0.29 per share, a year earlier; adjusted net income was $251.7 million, or $0.48 per share.
Opioid Settlement Framework totals about $774 million over nine years; first payment expected April 30, 2026 into escrow; after-tax net present value of about $482 million; subject to participation by states, political subdivisions and trib
Quarterly dividend raised 13% to $0.17 per share from $0.15, payable May 8, 2026 to holders of record as of April 24, 2026; remaining share repurchase authorization increased by $900 million to $2.0 billion.
Fiscal 2026 outlook: adjusted EBITDA of $3.850 billion to $3.925 billion and adjusted net income per share of $2.22 to $2.32, compared with $2.18 in fiscal 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.